Fusion imaging techniques and contrast-enhanced ultrasound for thermal ablation of hepatocellular carcinoma – A prospective randomized controlled trial

References

• Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301–1314.
   PubMed Web of Science ®Google Scholar
• Galle PR, Forner A, Llovet JM, et al. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236.
   PubMed Web of Science ®Google Scholar
• Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut. 2014;63(5):844–855.
   PubMed Web of Science ®Google Scholar
• Ahmed M, Solbiati L, Brace CL, et al. Image-guided tumor ablation: standardization of terminology and reporting criteria–a 10-year update. Radiology. 2014;273(1):241–260.
   PubMed Web of Science ®Google Scholar
• Claudon M, Dietrich CF, Choi BI, et al. Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) in the liver–update 2012: a WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. Ultrasound Med Biol. 2013;39(2):187–210.
   PubMed Web of Science ®Google Scholar
• Xu E, Long Y, Li K, et al. Comparison of CT/MRI-CEUS and US-CEUS fusion imaging techniques in the assessment of the thermal ablation of liver tumors. Int J Hyperthermia. 2018;35(1):159–167.
   PubMed Web of Science ®Google Scholar
• Minami Y, Nishida N, Kudo M. Therapeutic response assessment of RFA for HCC: contrast-enhanced US, CT and MRI. World J Gastroenterol. 2014;20(15):4160–4166.
   PubMed Web of Science ®Google Scholar
• Lee HY, Rhim H, Lee MW, et al. Early diffuse recurrence of hepatocellular carcinoma after percutaneous radiofrequency ablation: analysis of risk factors. Eur Radiol. 2013;23(1):190–197.
   PubMed Web of Science ®Google Scholar
• Abi-Jaoudeh N, Kruecker J, Kadoury S, et al. Multimodality image fusion-guided procedures: technique, accuracy, and applications. Cardiovasc Intervent Radiol. 2012;35(5):986–998.
   PubMed Web of Science ®Google Scholar
• Ahn S, Lee J, Lee D, et al. Real-time US-CT/MR fusion imaging for percutaneous radiofrequency ablation of hepatocellular carcinoma. J Hepatol. 2017;66(2):347–354.
   PubMed Web of Science ®Google Scholar
• Bo X, Xu H, Wang D, et al. Fusion imaging of contrast-enhanced ultrasound and contrast-enhanced CT or MRI before radiofrequency ablation for liver cancers. Br J Radiol. 2016;89(1067):20160379.
   PubMed Web of Science ®Google Scholar
• Li K, Su Z, Xu E, et al. Evaluation of the ablation margin of hepatocellular carcinoma using CEUS-CT/MR image fusion in a phantom model and in patients. BMC Cancer. 2017;17(1):61.
   PubMed Web of Science ®Google Scholar
• Li K, Su Z-Z, Xu E-J, et al. Improvement of ablative margins by the intraoperative use of CEUS-CT/MR image fusion in hepatocellular carcinoma. BMC Cancer. 2016;16(1):277.
   PubMed Web of Science ®Google Scholar
• Xu EJ, Lv SM, Li K, et al. Immediate evaluation and guidance of liver cancer thermal ablation by three-dimensional ultrasound/contrast-enhanced ultrasound fusion imaging. Int J Hyperthermia. 2018;34(6):870–876.
   PubMed Web of Science ®Google Scholar
• Ye J, Huang G, Zhang X, et al. Three-dimensional contrast-enhanced ultrasound fusion imaging predicts local tumor progression by evaluating ablative margin of radiofrequency ablation for hepatocellular carcinoma: a preliminary report. Int J Hyperthermia. 2019;36(1):55–64.
   PubMed Web of Science ®Google Scholar
• Lee D, Lee J, Lee J, et al. Radiofrequency ablation of hepatocellular carcinoma as first-line treatment: long-term results and prognostic factors in 162 patients with cirrhosis. Radiology. 2014;270(3):900–909.
   PubMed Web of Science ®Google Scholar
• Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020–1022.
   PubMed Web of Science ®Google Scholar
• Zhong-Zhen S, Kai L, Rong-Qin Z, et al. A feasibility study for determining ablative margin with 3D-CEUS-CT/MR image fusion after radiofrequency ablation of hepatocellular carcinoma. Ultraschall Med. 2012; 33:E250–E255.
   PubMedGoogle Scholar
• Xuan M, Zhou F, Ding Y, et al. Diagnostic accuracy of contrast-enhanced ultrasound in assessing the therapeutic response to radio frequency ablation for liver tumors: systematic review and meta-analysis. Surg Endosc. 2018;32(4):2067–2075.
   PubMed Web of Science ®Google Scholar
• Bo XW, Xu HX, Guo LH, et al. Ablative safety margin depicted by fusion imaging with post-treatment contrast-enhanced ultrasound and pre-treatment CECT/CEMRI after radiofrequency ablation for liver cancers. Br J Radiol. 2017;90(1078):20170063.
   PubMed Web of Science ®Google Scholar
• Minami Y, Minami T, Hagiwara S, et al. Ultrasound-ultrasound image overlay fusion improves real-time control of radiofrequency ablation margin in the treatment of hepatocellular carcinoma. Eur Radiol. 2018;28(5):1986–1993.
   PubMed Web of Science ®Google Scholar
• Du J, Li HL, Zhai B, et al. Radiofrequency ablation for hepatocellular carcinoma: utility of conventional ultrasound and contrast-enhanced ultrasound in guiding and assessing early therapeutic response and short-term follow-up results. Ultrasound Med Biol. 2015;41(9):2400–2411.
   PubMed Web of Science ®Google Scholar
• Nishigaki Y, Hayashi H, Tomita E, et al. Usefulness of contrast-enhanced ultrasonography using Sonazoid for the assessment of therapeutic response to percutaneous radiofrequency ablation for hepatocellular carcinoma. Hepatol Res. 2015;45(4):432–440.
   PubMed Web of Science ®Google Scholar
• Lee MW, Lim HK, Rhim H, et al. Percutaneous radiofrequency ablation of small (1–2 cm) hepatocellular carcinomas inconspicuous on B-mode ultrasonographic imaging: usefulness of combined fusion imaging with MRI and contrast-enhanced ultrasonography. Can J Gastroenterol Hepatol. 2018;2018:1.
   Web of Science ®Google Scholar
• Lim S, Lee MW, Rhim H, et al. Mistargeting after fusion imaging-guided percutaneous radiofrequency ablation of hepatocellular carcinomas. J Vasc Interv Radiol. 2014;25(2):307–314.
   PubMed Web of Science ®Google Scholar
• Yu J, Liang P, Yu XL, et al. Local tumour progression after ultrasound-guided microwave ablation of liver malignancies: risk factors analysis of 2529 tumours. Eur Radiol. 2015;25(4):1119–1126.
   PubMed Web of Science ®Google Scholar
• Nakazawa T, Kokubu S, Shibuya A, et al. Radiofrequency ablation of hepatocellular carcinoma: correlation between local tumor progression after ablation and ablative margin. Am J Roentgenol. 2007;188(2):480–488.
   PubMed Web of Science ®Google Scholar
• Okusaka T, Okada S, Ueno H, et al. Satellite lesions in patients with small hepatocellular carcinoma with reference to clinicopathologic features. Cancer. 2002;95(9):1931–1937.
   PubMed Web of Science ®Google Scholar
• Pinato DJ, Sharma R, Allara E, et al. The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma. J Hepatol. 2017;66(2):338–346.
   PubMed Web of Science ®Google Scholar
• Johnson PJ, Berhane S, Kagebayashi C, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2015;33(6):550–558.
   PubMed Web of Science ®Google Scholar
• Wang J, Zhang Z, Yan X, et al. Albumin-bilirubin (ALBI) as an accurate and simple prognostic score for chronic hepatitis B-related liver cirrhosis. Dig Liver Dis. 2019;51(8):1172–1178.
   PubMedGoogle Scholar
• Rhim H, Lee M, Kim Y, et al. Planning sonography to assess the feasibility of percutaneous radiofrequency ablation of hepatocellular carcinomas. Am J Roentgenol. 2008;190(5):1324–1330.
   PubMed Web of Science ®Google Scholar
• Thamtorawat S, Hicks R, Yu J, et al. Preliminary Outcome of microwave ablation of hepatocellular carcinoma: breaking the 3-cm barrier? J Vasc Interv Radiol. 2016;27(5):623–630.
   PubMed Web of Science ®Google Scholar